Equity Compensation (Tables)

9 Months Ended

Sep. 30, 2019

Equity Compensation [Abstract]

Schedule of Equity Compensation Expense and Related Income Tax Benefit Recognized

The following table summarizes the equity compensation expense and related income tax benefit recognized in the Consolidated Statements of Income (in thousands): 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Restricted awards:
Pre-tax compensation expense	$	1,310	$	1,028	$	3,786	$	3,091
Tax benefit	335		262		966		788
Restricted stock expense, net of tax	$	975	$	766	$	2,820	$	2,303
Performance awards:
Pre-tax compensation expense	$	680	$	992	$	2,577	$	2,319
Tax benefit	173		253		657		591
Performance award expense, net of tax	$	507	$	739	$	1,920	$	1,728

Schedule of Equity Compensation Stock Options Activity

The following table summarizes stock option activity for the nine months ended September 30, 2019:

	Number of Options (in thousands)		Weighted Average Exercise Price ($)		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)
Outstanding at beginning of period	9		$	19.02
Granted	—		—
Exercised	(9	)	19.02
Forfeited	—		—
Expired	—		—
Outstanding at end of period	—		—		0.00	$	—
Exercisable at end of period	—		—		0.00	$	—

Schedule of Equity Compensation, Restricted Award Activity

The following table summarizes restricted award activity for the nine months ended September 30, 2019:

	Number of Restricted Awards (in thousands)		Weighted Average Grant Date Fair Value ($)
Nonvested at beginning of period	326		$	31.93
Granted	147		32.55
Vested	(53	)	33.04
Forfeited	(9	)	31.55
Nonvested at end of period	411		32.02

Schedule of Equity Compensation Performance Award Activity

The following table summarizes performance award activity for the nine months ended September 30, 2019:

	Number of Performance Awards (in thousands)		Weighted Average Grant Date Fair Value ($)
Nonvested at beginning of period	207		$	27.92
Granted	97		32.88
Vested	(35	)	27.07
Forfeited	—		—
Nonvested at end of period	269		30.40